Blog

Kymos celebrates the recent purchase of two new API-6500 plus instruments, the most sensitive in the market, to boost our bioanalytical capabilities for small molecules in our Frankfurt und Barcelona sites. Together with our third API-6500 coupled to an Agilent UHPLC, two high-sensitivity APIs 5500 connected to a Waters UPLC Acquity, six API-4000 and one API-3200 (all triple SCIEX quadrupoles) we are now capable to process more than 31,000 bioanalytical samples per month.

The new COVID-19 vaccine developed by Pfizer/BioNTech was approved by the EMA last December and now Moderna’s is following suit. Both are based on mRNA technology and represent a very different type of vaccine compared to traditional ones. While the general public is just beginning to discover mRNA technology, Dr. Meike Saul is an expert in RNA research and has worked with Prolytic GmbH for many years. She was invited to give us a better insight into the exciting world of RNA.

We at KYMOS and ASPHALION are long-time partners in providing analytical and regulatory services to international pharma and biotech sectors. Our testimony goes beyond the conventional “CRO trading with UK clients” to overcome internalization barriers. Our respective services are part of a complex international supply chain that makes the effects of Brexit more visible and quantifiable. Quality Control (QC) is one of the most interdisciplinary departments at KYMOS with high demand from international clients, particularly for EU Batch Testing and Release for drug products and IMPs.

The awards ceremony was held during the CataloniaBio & HealthTech Gala, shared via live streaming.

Judit Anido, president of CataloniaBio & HealthTech: “We need more success stories like Kymos. One of the biggest challenges we are facing as a sector is to consolidate the business sphere”